North America to Witness Significant Growth from 2021 To 2026

Northbrook, IL -- (SBWire) -- 03/29/2022 --According to the new market research report "eClinical Solutions Market by Clinical trial phases, Product (CDMS, EDC, CTMS, eCOA, RTSM, ETMF, Analytics, Integration, Safety), Delivery (Web-based, On demand, On premise, Cloud), End user (Pharma & Biotech, Hospitals, CROs) - Global Forecasts to 2026", published by MarketsandMarkets™, the eClinical Solutions Market is projected to reach USD 15.4 billion by 2026 from USD 8.3 billion in 2021 at a CAGR of 13.3%.

Growth Drivers: Growing adoption of novel software solutions in clinical research;

It takes ~13 years and overall investment of up to USD 1.3 billion (~USD 146 million per year) to commercialize a successful drug candidate; this includes initial drug screening, product synthesis, preclinical and clinical studies, as well as regulatory filing and approval.

Therefore, researchers increasingly prefer innovative eClinical solutions that offer improved efficiency of clinical trials, enhance site performance, and streamline research workload with higher cost efficiency compared to conventional methodologies. These software solutions allow pharmaceutical companies as well as independent researchers to compare the operating characteristics of the software design options; model, forecast, and track clinical trial enrolment; and identify the procedural bottlenecks associated with clinical trials. The procedural and operational benefits offered by eClinical solutions are resulting in significant growth in the adoption of these solutions among CROs independent researchers, as well as pharmaceutical, medical device, and biotechnology companies for their clinical research programs.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=553

The Growth in the eClinical Solutions market can primarily be attributed to factors such as increasing operational costs and regulatory requirements associated with clinical research studies, government grants to support clinical trials, and growing R&D expenditure on drug development by pharma-biotech companies.

The companies have a large market spread across various countries in North America, Europe, Asia Pacific, and the Rest of the World.

Coronavirus disease 2019 (COVID-19) is an acute respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Largely unknown before the outbreak began in Wuhan, China, in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. The clinical trials market is shifting toward digital ways of working, and the COVID-19 outbreak is likely to both accelerate this trend and drive long-term changes to historically accepted trial management norms. If virtual and remote working modes prove to be sustainable methods of conducting a trial, it can be a great opportunity for all eClinical solutions providers.

Cloud-based (SaaS) segment is projected to record the highest CAGR

Based on delivery mode, the global eClinical solutions market is segmented into web-hosted (on-demand), licensed enterprise (on-premises), and cloud-based (SaaS) solutions. In 2020, the web-hosted (on-demand) segment commanded the largest share of the global market. The increasing number of cloud-based clinical trial solutions in the market and the rising adoption of these solutions in clinical research studies (owing to advantages such as ease of integration, quicker deployment, and flexible scalability with a fixed monthly fee) are fueling the growth of the cloud-based Electronic Data Capture and Clinical Data Management Systems Market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=553

Phase III clinical trials is expected to register the highest growth during the forecast period

Based on clinical trial phase, the eClinical solutions market has been segmented into phase I, phase II, phase III, and phase IV trials. The phase III clinical trials segment accounted for the largest share of the market in 2020. The large share of this segment is attributed to the high demand for eClinical solutions for phase III trials due to the involvement of thousands of patients in this phase

CROs segment is estimated to record the highest CAGR in the forecast period.

Based on end user, the global eClinical solutions market is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations, consulting service companies, medical device manufacturers, hospitals, and academic research institutions. The pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the market in 2020. However, the CROs segment is estimated to record the highest CAGR (15.5%) in the next five years. The increasing number of CROs in developed as well as developing countries, and the rising instances of clinical trial outsourcing to specialized clinical research organizations are responsible for the high growth rate of this segment.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=553

In 2020, North America commanded the largest share of the eClinical solutions market. Increasing government grants to support clinical trials, continuous product development and new product launches by eClinical solution vendors, and growth in the number of partnerships for new drug development are further stimulating the demand for eClinical solutions in this region.

Some of the prominent players in this Electronic Data Capture and Clinical Data Management Systems Market are Oracle Corporation (US), Medidata Solutions, Inc. (US), Parexel International Corporation (US), BioClinica, Inc. (US), Signant Health (US), Datatrak International, Inc. (US), ERT (US), eClinical Solutions, Inc. (US), MaxisIT Inc. (US), Bio-Optronics, Inc. (US), Merge Healthcare Incorporated (US), and OmniComm Systems, Inc. (US)